PMS-IPRATROPIUM SOLUTION

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

IPRATROPIUM BROMIDE

Предлага се от:

PHARMASCIENCE INC

АТС код:

R03BB01

INN (Международно Name):

IPRATROPIUM BROMIDE

дозиране:

250MCG

Лекарствена форма:

SOLUTION

Композиция:

IPRATROPIUM BROMIDE 250MCG

Начин на приложение:

INHALATION

Броя в опаковка:

20ML

Вид предписание :

Prescription

Терапевтична област:

ANTIMUSCARINICS ANTISPASMODICS

Каталог на резюме:

Active ingredient group (AIG) number: 0115643001; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2014-01-20

Данни за продукта

PRODUCT MONOGRAPH
PMS-IPRATROPIUM
Ipratropium Bromide Nebulizer Solution
250 mcg/mL (0.025%) in 20 mL Bottles
BRONCHODILATOR
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montreal, Quebec
H4P 2T4
www.pharmascience.com
DATE OF REVISION:
May 11, 2017
CONTROL NO.: 204492
_pms-IPRATROPIUM Product Monograph Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
3
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
......................................................................................................
7
DRUG INTERACTIONS
....................................................................................................
10
DOSAGE AND ADMINISTRATION
................................................................................
10
OVERDOSAGE
...................................................................................................................
11
ACTION AND CLINICAL
PHARMACOLOGY...............................................................
11
STORAGE AND STABILITY
............................................................................................
14
SPECIAL HANDLING INSTRUCTIONS
.........................................................................
15
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 15
PART II: SCIENTIFIC INFORMATION
..........................................................................
16
PHARMACEUTICAL INFORMATION
............................................................................
16
CLINICAL TRIALS
...........................